Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen G O'Brien

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Hematology/Oncology Clinics of North America|July 24, 2004
Imatinib therapy in chronic myeloid leukemiaLucy C Crossman, Stephen G O'Brien
British Journal of Haematology|October 3, 2002
Position paper on imatinib mesylate in chronic myeloid leukaemiaStephen G O'Brien, Simon A J Rule
Seminars in Hematology|June 5, 2003
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, Michael W N Deininger
Blood|November 5, 2002
Managing cutaneous reactions to imatinib therapySimon A J Rule, Stephen G O'Brien, Lucy C Crossman
Hematology. American Society of Hematology. Education Program|November 26, 2002
Chronic myelogenous leukemiaBrian J Druker, Stephen G O'Brien, Jorge Cortes, et al.
Blood|December 7, 2007
Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemiaUdo Holtick, Scott R Marshall, Stephen G O'Brien, et al.
British Journal of Haematology|October 3, 2002
Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluidNobuyuki Takayama, Norihide Sato, Stephen G O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2003
Practical management of patients with chronic myeloid leukemia receiving imatinibMichael W N Deininger, Stephen G O'Brien, John M Ford, et al.
Haematologica|August 4, 2009
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trialFrançois Guilhot, Brian Druker, Richard A Larson, et al.
Blood|April 20, 2002
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocationStephen G O'Brien, Sara A D Vieira, Samantha Connors, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Hematology/Oncology Clinics of North America|July 24, 2004
Imatinib therapy in chronic myeloid leukemiaLucy C Crossman, Stephen G O'Brien
British Journal of Haematology|October 3, 2002
Position paper on imatinib mesylate in chronic myeloid leukaemiaStephen G O'Brien, Simon A J Rule
Seminars in Hematology|June 5, 2003
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, Michael W N Deininger
Blood|November 5, 2002
Managing cutaneous reactions to imatinib therapySimon A J Rule, Stephen G O'Brien, Lucy C Crossman
Hematology. American Society of Hematology. Education Program|November 26, 2002
Chronic myelogenous leukemiaBrian J Druker, Stephen G O'Brien, Jorge Cortes, et al.
Blood|December 7, 2007
Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemiaUdo Holtick, Scott R Marshall, Stephen G O'Brien, et al.
British Journal of Haematology|October 3, 2002
Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluidNobuyuki Takayama, Norihide Sato, Stephen G O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2003
Practical management of patients with chronic myeloid leukemia receiving imatinibMichael W N Deininger, Stephen G O'Brien, John M Ford, et al.
Haematologica|August 4, 2009
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trialFrançois Guilhot, Brian Druker, Richard A Larson, et al.
Blood|April 20, 2002
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocationStephen G O'Brien, Sara A D Vieira, Samantha Connors, et al.
Pageof 3